Faron Pharmaceuticals Oy (AIM: FARN)

London flag London · Delayed Price · Currency is GBP · Price in GBX
192.50
-2.50 (-1.28%)
Jan 21, 2025, 4:23 PM GMT+1
-20.10%
Market Cap 201.40M
Revenue (ttm) n/a
Net Income (ttm) -26.80M
Shares Out 104.62M
EPS (ttm) -0.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,910
Average Volume 11,616
Open 200.00
Previous Close 195.00
Day's Range 190.00 - 200.00
52-Week Range 85.00 - 318.00
Beta 0.28
RSI 55.60
Earnings Date Feb 27, 2025

About Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. T... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 34
Stock Exchange London Stock Exchange AIM
Ticker Symbol FARN
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

News

There is no news available yet.